nodes	percent_of_prediction	percent_of_DWPC	metapath
Alvimopan—Indinavir—acquired immunodeficiency syndrome	0.577	1	CrCtD
Alvimopan—Indinavir—Nelfinavir—acquired immunodeficiency syndrome	0.143	0.389	CrCrCtD
Alvimopan—Indinavir—Lopinavir—acquired immunodeficiency syndrome	0.116	0.317	CrCrCtD
Alvimopan—Indinavir—Saquinavir—acquired immunodeficiency syndrome	0.108	0.295	CrCrCtD
Alvimopan—Connective tissue disorder—Amprenavir—acquired immunodeficiency syndrome	0.000667	0.0189	CcSEcCtD
Alvimopan—Malnutrition—Amprenavir—acquired immunodeficiency syndrome	0.000591	0.0168	CcSEcCtD
Alvimopan—Flatulence—Amprenavir—acquired immunodeficiency syndrome	0.000582	0.0165	CcSEcCtD
Alvimopan—Connective tissue disorder—Nevirapine—acquired immunodeficiency syndrome	0.000547	0.0155	CcSEcCtD
Alvimopan—Hypokalaemia—Efavirenz—acquired immunodeficiency syndrome	0.00054	0.0153	CcSEcCtD
Alvimopan—Flatulence—Didanosine—acquired immunodeficiency syndrome	0.000531	0.0151	CcSEcCtD
Alvimopan—Connective tissue disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000529	0.015	CcSEcCtD
Alvimopan—Connective tissue disorder—Stavudine—acquired immunodeficiency syndrome	0.000528	0.015	CcSEcCtD
Alvimopan—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000521	0.029	CbGpPWpGaD
Alvimopan—Connective tissue disorder—Abacavir—acquired immunodeficiency syndrome	0.00052	0.0148	CcSEcCtD
Alvimopan—Urinary retention—Ritonavir—acquired immunodeficiency syndrome	0.000499	0.0142	CcSEcCtD
Alvimopan—Anaemia—Didanosine—acquired immunodeficiency syndrome	0.000498	0.0141	CcSEcCtD
Alvimopan—Malnutrition—Nelfinavir—acquired immunodeficiency syndrome	0.000469	0.0133	CcSEcCtD
Alvimopan—Malnutrition—Stavudine—acquired immunodeficiency syndrome	0.000468	0.0133	CcSEcCtD
Alvimopan—OPRM1—nerve—acquired immunodeficiency syndrome	0.000467	0.255	CbGeAlD
Alvimopan—Flatulence—Nelfinavir—acquired immunodeficiency syndrome	0.000462	0.0131	CcSEcCtD
Alvimopan—Urinary tract disorder—Zidovudine—acquired immunodeficiency syndrome	0.000461	0.0131	CcSEcCtD
Alvimopan—Flatulence—Stavudine—acquired immunodeficiency syndrome	0.000461	0.0131	CcSEcCtD
Alvimopan—Malnutrition—Abacavir—acquired immunodeficiency syndrome	0.000461	0.0131	CcSEcCtD
Alvimopan—Hypokalaemia—Saquinavir—acquired immunodeficiency syndrome	0.00046	0.013	CcSEcCtD
Alvimopan—Connective tissue disorder—Zidovudine—acquired immunodeficiency syndrome	0.000459	0.013	CcSEcCtD
Alvimopan—Urethral disorder—Zidovudine—acquired immunodeficiency syndrome	0.000458	0.013	CcSEcCtD
Alvimopan—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000457	0.0254	CbGpPWpGaD
Alvimopan—Back pain—Nelfinavir—acquired immunodeficiency syndrome	0.000454	0.0129	CcSEcCtD
Alvimopan—Back pain—Stavudine—acquired immunodeficiency syndrome	0.000452	0.0128	CcSEcCtD
Alvimopan—Anaemia—Nevirapine—acquired immunodeficiency syndrome	0.000448	0.0127	CcSEcCtD
Alvimopan—Anaemia—Nelfinavir—acquired immunodeficiency syndrome	0.000433	0.0123	CcSEcCtD
Alvimopan—Anaemia—Stavudine—acquired immunodeficiency syndrome	0.000432	0.0123	CcSEcCtD
Alvimopan—Urinary tract disorder—Indinavir—acquired immunodeficiency syndrome	0.000429	0.0122	CcSEcCtD
Alvimopan—Connective tissue disorder—Indinavir—acquired immunodeficiency syndrome	0.000427	0.0121	CcSEcCtD
Alvimopan—Anaemia—Abacavir—acquired immunodeficiency syndrome	0.000426	0.0121	CcSEcCtD
Alvimopan—Urethral disorder—Indinavir—acquired immunodeficiency syndrome	0.000426	0.0121	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.000416	0.0118	CcSEcCtD
Alvimopan—Malnutrition—Zidovudine—acquired immunodeficiency syndrome	0.000406	0.0115	CcSEcCtD
Alvimopan—Urinary tract disorder—Efavirenz—acquired immunodeficiency syndrome	0.000405	0.0115	CcSEcCtD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000405	0.0225	CbGpPWpGaD
Alvimopan—Connective tissue disorder—Efavirenz—acquired immunodeficiency syndrome	0.000403	0.0114	CcSEcCtD
Alvimopan—Urethral disorder—Efavirenz—acquired immunodeficiency syndrome	0.000402	0.0114	CcSEcCtD
Alvimopan—Flatulence—Zidovudine—acquired immunodeficiency syndrome	0.0004	0.0114	CcSEcCtD
Alvimopan—Back pain—Zidovudine—acquired immunodeficiency syndrome	0.000393	0.0112	CcSEcCtD
Alvimopan—Dyspepsia—Didanosine—acquired immunodeficiency syndrome	0.000387	0.011	CcSEcCtD
Alvimopan—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000386	0.0215	CbGpPWpGaD
Alvimopan—Malnutrition—Indinavir—acquired immunodeficiency syndrome	0.000378	0.0107	CcSEcCtD
Alvimopan—Anaemia—Zidovudine—acquired immunodeficiency syndrome	0.000376	0.0107	CcSEcCtD
Alvimopan—Flatulence—Indinavir—acquired immunodeficiency syndrome	0.000372	0.0106	CcSEcCtD
Alvimopan—Back pain—Indinavir—acquired immunodeficiency syndrome	0.000366	0.0104	CcSEcCtD
Alvimopan—Urinary tract disorder—Ritonavir—acquired immunodeficiency syndrome	0.000358	0.0102	CcSEcCtD
Alvimopan—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.000357	0.0101	CcSEcCtD
Alvimopan—Connective tissue disorder—Ritonavir—acquired immunodeficiency syndrome	0.000357	0.0101	CcSEcCtD
Alvimopan—Urethral disorder—Ritonavir—acquired immunodeficiency syndrome	0.000356	0.0101	CcSEcCtD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000355	0.0197	CbGpPWpGaD
Alvimopan—Flatulence—Efavirenz—acquired immunodeficiency syndrome	0.000352	0.00998	CcSEcCtD
Alvimopan—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.000349	0.00991	CcSEcCtD
Alvimopan—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.000345	0.0098	CcSEcCtD
Alvimopan—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.000345	0.00979	CcSEcCtD
Alvimopan—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.000343	0.00974	CcSEcCtD
Alvimopan—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.000342	0.00972	CcSEcCtD
Alvimopan—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000342	0.00969	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000341	0.00968	CcSEcCtD
Alvimopan—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.000337	0.00956	CcSEcCtD
Alvimopan—Flatulence—Delavirdine—acquired immunodeficiency syndrome	0.000337	0.00955	CcSEcCtD
Alvimopan—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.000336	0.00953	CcSEcCtD
Alvimopan—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.00033	0.00938	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00033	0.00938	CcSEcCtD
Alvimopan—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.00033	0.00936	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000329	0.00935	CcSEcCtD
Alvimopan—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.000327	0.00929	CcSEcCtD
Alvimopan—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000326	0.00926	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000325	0.00921	CcSEcCtD
Alvimopan—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000316	0.00896	CcSEcCtD
Alvimopan—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.000316	0.00896	CcSEcCtD
Alvimopan—Flatulence—Ritonavir—acquired immunodeficiency syndrome	0.000311	0.00883	CcSEcCtD
Alvimopan—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000306	0.00867	CcSEcCtD
Alvimopan—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000304	0.00863	CcSEcCtD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.0003	0.0167	CbGpPWpGaD
Alvimopan—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.0003	0.0085	CcSEcCtD
Alvimopan—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000294	0.00835	CcSEcCtD
Alvimopan—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.00828	CcSEcCtD
Alvimopan—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000292	0.00828	CcSEcCtD
Alvimopan—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000291	0.0162	CbGpPWpGaD
Alvimopan—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.00823	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000286	0.00812	CcSEcCtD
Alvimopan—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000286	0.00811	CcSEcCtD
Alvimopan—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000284	0.00805	CcSEcCtD
Alvimopan—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.00797	CcSEcCtD
Alvimopan—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000281	0.00796	CcSEcCtD
Alvimopan—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000274	0.0152	CbGpPWpGaD
Alvimopan—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000272	0.0077	CcSEcCtD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000271	0.0151	CbGpPWpGaD
Alvimopan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.00761	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000266	0.00756	CcSEcCtD
Alvimopan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000264	0.00748	CcSEcCtD
Alvimopan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.00728	CcSEcCtD
Alvimopan—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000255	0.0142	CbGpPWpGaD
Alvimopan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.00714	CcSEcCtD
Alvimopan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000249	0.00707	CcSEcCtD
Alvimopan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.00696	CcSEcCtD
Alvimopan—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000245	0.0136	CbGpPWpGaD
Alvimopan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.00683	CcSEcCtD
Alvimopan—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00024	0.0133	CbGpPWpGaD
Alvimopan—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000238	0.00677	CcSEcCtD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000238	0.0132	CbGpPWpGaD
Alvimopan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.00644	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.00632	CcSEcCtD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000222	0.0123	CbGpPWpGaD
Alvimopan—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.00626	CcSEcCtD
Alvimopan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.0062	CcSEcCtD
Alvimopan—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000216	0.012	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000215	0.012	CbGpPWpGaD
Alvimopan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000214	0.00608	CcSEcCtD
Alvimopan—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.00602	CcSEcCtD
Alvimopan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.00591	CcSEcCtD
Alvimopan—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000207	0.0115	CbGpPWpGaD
Alvimopan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.0058	CcSEcCtD
Alvimopan—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000203	0.0113	CbGpPWpGaD
Alvimopan—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.00574	CcSEcCtD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000201	0.0112	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000194	0.0108	CbGpPWpGaD
Alvimopan—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000188	0.0104	CbGpPWpGaD
Alvimopan—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000182	0.0101	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000181	0.0101	CbGpPWpGaD
Alvimopan—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000177	0.00985	CbGpPWpGaD
Alvimopan—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000177	0.00985	CbGpPWpGaD
Alvimopan—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000172	0.00958	CbGpPWpGaD
Alvimopan—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000165	0.00915	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000164	0.00914	CbGpPWpGaD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000164	0.00913	CbGpPWpGaD
Alvimopan—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000154	0.0841	CbGeAlD
Alvimopan—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000153	0.00852	CbGpPWpGaD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000151	0.00842	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000149	0.00827	CbGpPWpGaD
Alvimopan—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000148	0.081	CbGeAlD
Alvimopan—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000148	0.0807	CbGeAlD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000144	0.00802	CbGpPWpGaD
Alvimopan—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000142	0.0777	CbGeAlD
Alvimopan—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000139	0.00773	CbGpPWpGaD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000137	0.00761	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000133	0.00738	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00013	0.00725	CbGpPWpGaD
Alvimopan—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.00013	0.00723	CbGpPWpGaD
Alvimopan—OPRM1—blood—acquired immunodeficiency syndrome	0.000129	0.0707	CbGeAlD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000129	0.00716	CbGpPWpGaD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000129	0.00716	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000125	0.00696	CbGpPWpGaD
Alvimopan—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000125	0.0681	CbGeAlD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000122	0.00678	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00012	0.00668	CbGpPWpGaD
Alvimopan—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000119	0.00661	CbGpPWpGaD
Alvimopan—OPRD1—brain—acquired immunodeficiency syndrome	0.000118	0.0643	CbGeAlD
Alvimopan—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000116	0.00642	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000113	0.0063	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000113	0.00628	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000113	0.00628	CbGpPWpGaD
Alvimopan—OPRK1—brain—acquired immunodeficiency syndrome	0.000113	0.0617	CbGeAlD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000112	0.00624	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00011	0.00613	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00011	0.0061	CbGpPWpGaD
Alvimopan—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000109	0.00604	CbGpPWpGaD
Alvimopan—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000109	0.00604	CbGpPWpGaD
Alvimopan—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000107	0.00596	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000106	0.0059	CbGpPWpGaD
Alvimopan—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000105	0.0574	CbGeAlD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000102	0.00565	CbGpPWpGaD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000101	0.00564	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000101	0.00563	CbGpPWpGaD
Alvimopan—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000101	0.0553	CbGeAlD
Alvimopan—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000101	0.00561	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	9.93e-05	0.00552	CbGpPWpGaD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	9.8e-05	0.00545	CbGpPWpGaD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	9.54e-05	0.00531	CbGpPWpGaD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	9.54e-05	0.00531	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	9.52e-05	0.0053	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	9.52e-05	0.0053	CbGpPWpGaD
Alvimopan—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.4e-05	0.00523	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.3e-05	0.00517	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	9.28e-05	0.00516	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.19e-05	0.00511	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	8.91e-05	0.00495	CbGpPWpGaD
Alvimopan—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	8.84e-05	0.00492	CbGpPWpGaD
Alvimopan—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	8.82e-05	0.00491	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.64e-05	0.0048	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.64e-05	0.0048	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	8.59e-05	0.00478	CbGpPWpGaD
Alvimopan—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	8.56e-05	0.00476	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	8.39e-05	0.00467	CbGpPWpGaD
Alvimopan—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.26e-05	0.0046	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.05e-05	0.00448	CbGpPWpGaD
Alvimopan—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	8.05e-05	0.00448	CbGpPWpGaD
Alvimopan—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	8.05e-05	0.00448	CbGpPWpGaD
Alvimopan—OPRM1—brain—acquired immunodeficiency syndrome	8.02e-05	0.0439	CbGeAlD
Alvimopan—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	7.95e-05	0.00442	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	7.86e-05	0.00437	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	7.74e-05	0.0043	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.73e-05	0.0043	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.57e-05	0.00421	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.57e-05	0.00421	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.53e-05	0.00419	CbGpPWpGaD
Alvimopan—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.47e-05	0.00415	CbGpPWpGaD
Alvimopan—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	7.47e-05	0.00415	CbGpPWpGaD
Alvimopan—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.44e-05	0.00414	CbGpPWpGaD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	7.26e-05	0.00404	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	7.25e-05	0.00403	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.99e-05	0.00389	CbGpPWpGaD
Alvimopan—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.91e-05	0.00384	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	6.81e-05	0.00379	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.78e-05	0.00377	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.58e-05	0.00366	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.58e-05	0.00366	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.57e-05	0.00365	CbGpPWpGaD
Alvimopan—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	6.54e-05	0.00364	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.53e-05	0.00363	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.42e-05	0.00357	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.4e-05	0.00356	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.4e-05	0.00356	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.26e-05	0.00348	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.13e-05	0.00341	CbGpPWpGaD
Alvimopan—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	6.12e-05	0.00341	CbGpPWpGaD
Alvimopan—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.06e-05	0.00337	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.92e-05	0.00329	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.81e-05	0.00323	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.77e-05	0.00321	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.77e-05	0.00321	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.76e-05	0.0032	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.73e-05	0.00319	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.63e-05	0.00313	CbGpPWpGaD
Alvimopan—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	5.52e-05	0.00307	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.49e-05	0.00305	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.19e-05	0.00289	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.18e-05	0.00288	CbGpPWpGaD
Alvimopan—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.12e-05	0.00285	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.09e-05	0.00283	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5e-05	0.00278	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.87e-05	0.00271	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.87e-05	0.00271	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.87e-05	0.00271	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.76e-05	0.00265	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.64e-05	0.00258	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.51e-05	0.00251	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.39e-05	0.00244	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.39e-05	0.00244	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.31e-05	0.00239	CbGpPWpGaD
Alvimopan—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	4.04e-05	0.00225	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.97e-05	0.00221	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.95e-05	0.0022	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.95e-05	0.0022	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.8e-05	0.00211	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.8e-05	0.00211	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.72e-05	0.00207	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.72e-05	0.00207	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.71e-05	0.00206	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.59e-05	0.002	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.48e-05	0.00194	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.47e-05	0.00193	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.43e-05	0.00191	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.38e-05	0.00188	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.38e-05	0.00188	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.34e-05	0.00186	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.33e-05	0.00185	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.33e-05	0.00185	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.26e-05	0.00181	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.26e-05	0.00181	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.15e-05	0.00175	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.01e-05	0.00167	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.96e-05	0.00165	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.96e-05	0.00165	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.94e-05	0.00164	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.93e-05	0.00163	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.83e-05	0.00157	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.81e-05	0.00156	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.81e-05	0.00156	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.79e-05	0.00155	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.75e-05	0.00153	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.75e-05	0.00153	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.66e-05	0.00148	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.57e-05	0.00143	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.55e-05	0.00142	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.54e-05	0.00141	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.53e-05	0.00141	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.5e-05	0.00139	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.5e-05	0.00139	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.48e-05	0.00138	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.44e-05	0.00136	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.34e-05	0.0013	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.31e-05	0.00129	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.25e-05	0.00125	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.23e-05	0.00124	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.22e-05	0.00123	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.12e-05	0.00118	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.1e-05	0.00117	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.06e-05	0.00115	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.06e-05	0.00114	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.03e-05	0.00113	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.99e-05	0.00111	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.99e-05	0.00111	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.9e-05	0.00106	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.89e-05	0.00105	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.87e-05	0.00104	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.86e-05	0.00103	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.75e-05	0.000972	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.75e-05	0.000972	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.74e-05	0.000966	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.71e-05	0.000953	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.57e-05	0.000874	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.52e-05	0.000843	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.49e-05	0.000831	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.48e-05	0.000822	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.48e-05	0.000822	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.47e-05	0.000818	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.37e-05	0.00076	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.34e-05	0.000743	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.33e-05	0.00074	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.31e-05	0.000728	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.29e-05	0.000718	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.2e-05	0.000666	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000652	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.12e-05	0.000625	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.11e-05	0.000616	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000607	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.01e-05	0.000563	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.9e-06	0.000551	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.9e-06	0.000439	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.86e-06	0.000437	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.92e-06	0.000385	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.89e-06	0.000383	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.85e-06	0.000325	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.82e-06	0.000324	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.64e-06	0.000258	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.07e-06	0.000226	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.44e-06	0.000191	CbGpPWpGaD
